These include Onbrez Inhalation Capsules 150 mcg (indacaterol maleate), which were launched in Japan on September 20, 2011, and, if approved, the investigational drugs NVA237 (glycopyrronium bromide) and QVA149 (fixed-dose combination of indacaterol maleate and glycopyrronium bromide), both of which are currently in Phase III development.
Based on this agreement, the two companies will begin co-promoting Onbrez on December 1, 2011.
While Novartis Pharma will concentrate its promotional activities on university and flagship hospitals, Eisai will target other healthcare providers including general hospitals and primary care physicians.
The manufacture and sale of Onbrez will be handled by Novartis Pharma in the same way as before, with the two companies commencing co-promotion of NVA237 and QVA149 following their launch.
The new co-promotion agreement is a partnership of mutual commitment between Eisai and Novartis Pharma.
Novartis Pharma aims to maximize the value of Onbrez, a new long-acting bronchodilator that provides sustained 24-hour efficacy and has a rapid onset of action at first dose, as well as NVA237 and QVA149, which combines indacaterol together with NVA237, while Eisai seeks to further enhance its product portfolio in the area of internal medicine.
With the conclusion of the co-promotion agreement, Eisai and Novartis seek to establish a greater presence in the field of COPD and achieve a synergistic effect, thereby making further contributions to address the unmet needs of, and increase the benefits provided to, COPD patients.
Purchase the on-demand report Partnering Agreements with Eisai
See the full deal data at Current Agreements (subscription required)